Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 19

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma89Dermatitis atopic89HIV infection78Rheumatoid arthritis75Systemic lupus erythematosus63Multiple sclerosis59Psoriasis54Psoriatic arthropathy46Myasthenia gravis44Type 1 diabetes mellitus41Systemic scleroderma40Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Sjogren's syndrome31Cardiac amyloidosis29Interstitial lung disease29Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy24Vitiligo24Hereditary angioedema22Axial spondyloarthritis21+269

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Systemic lupus erythematosus

Recruiting

Study of Mosunetuzumab Treatment in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mosunetuzumab
  • Sponsor:F. Hoffmann-La Roche AG

Myelodysplastic syndrome+1

Recruiting

Study of momelotinib in patients with VEXAS syndrome and myelodysplastic syndrome who are dependent on or do not respond to steroid treatment

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Groupe Francophone Des Myelodysplasies

IgA nephropathy

Recruiting

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Biogen Idec Research Limited

Dermatitis atopic

Recruiting

Study of GHZ339 for treatment of moderate to severe atopic dermatitis

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:GHZ339
  • Sponsor:Novartis Pharma AG

Rhinitis allergic+1

Recruiting

Study of sublingual immunotherapy with Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen mix for patients with dust mite allergic rhinitis

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Advanced Outcomes Research S.L.

Vitiligo

Recruiting

Study of Ritlecitinib Combined with Narrow Band UVB Light Therapy Compared to Ritlecitinib Alone in Adults with Vitiligo

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Centre Hospitalier Universitaire De Nice

Type 1 diabetes mellitus

Recruiting

Study of Colchicine to Reduce Complications in People with Type 1 Diabetes and High Blood Sugar Variability

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Stichting Radboud universitair medisch centrum

Type 1 diabetes mellitus+1

Recruiting

Study of IMMUNOSTEM gene therapy using modified stem cells for newly diagnosed patients with type 1 diabetes who still produce insulin

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:IMMUNOSTEM
  • Sponsor:Altheia Science S.r.l.

Idiopathic pulmonary fibrosis

Recruiting

Study of MTX-463 compared to placebo to assess its safety and effectiveness in adults with idiopathic pulmonary fibrosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glucose Monohydrate
  • Sponsor:Mediar Therapeutics Inc.

Disease risk factor+1

Recruiting

Study of cardiovascular disease prevention using carotid ultrasound in patients with inflammatory rheumatic diseases treated with amlodipine, atorvastatin, rosuvastatin, ezetimibe and bempedoic acid

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Amlodipine
  • Sponsor:Instituto De Investigacion Marques De Valdecilla

Immune thrombocytopenia

Recruiting

Study of efgartigimod given by IV infusion in adolescents aged 12-17 years with chronic immune thrombocytopenia

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Acute respiratory distress syndrome

Recruiting

Study of inhaled aprotinin for treatment of moderate to severe acute respiratory distress syndrome

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aprotinin
  • Sponsor:Fundacion Del Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine40 clinical trialsTenofovir Alafenamide38 clinical trialsTocilizumab38 clinical trialsMethotrexate37 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.